Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares rose more than +10% in pre-market trading to $32.
In a research report published Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on TG Therapeutics Inc (NASDAQ:TGTX) with a $22 price target, which …
